Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics (ANIK)
NASDAQ:ANIK
Holding ANIK?
Track your performance easily
ANIK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.81 - $29.12
Previous Close$25.2
Volume43.59K
Average Volume (3M)46.55K
Market Cap
$372.88M
Enterprise Value$302.07M
Total Cash (Recent Filing)$96.59M
Total Debt (Recent Filing)$25.79M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 06, 2024EPS Estimate
$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.06
Shares Outstanding14,796,726
10 Day Avg. Volume36,615
30 Day Avg. Volume46,545
Standard Deviation0.11
R-Squared0.15
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.79
Price to Sales (P/S)2.23
Price to Cash Flow (P/CF)-87.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.77
Enterprise Value/Gross Profit2.93
Enterprise Value/Ebitda92.07
Forecast
1Y Price Target
$37.00Price Target Upside45.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Anika Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial GuidanceManagement affirmed its previous financial guidance for FY/24, indicating confidence in future performance.
Revenue GrowthAnika generated $40.5 million in revenue, a 6.9% increase versus the estimate.
Strong Financial PositionThe company ended the quarter with $68.6 million in cash and equivalents and no debt.
Bears Say
Cash FlowOperating cash flow in the quarter was -$0.1 million.
EarningsAdjusted EPS of $0.09 were light relative to the $0.14 estimate.
Financial PerformanceAdjusted EBITDA was $2.5 million and fell short of the $3.9 million expectation.
---
Ownership Overview
16.93% Insiders
20.78% Mutual Funds
51.21% Other Institutional Investors
11.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ANIK FAQ
What was Anika Therapeutics’s price range in the past 12 months?
Anika Therapeutics lowest stock price was $16.81 and its highest was $29.11 in the past 12 months.
What is Anika Therapeutics’s market cap?
Currently, no data Available
When is Anika Therapeutics’s upcoming earnings report date?
Anika Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were Anika Therapeutics’s earnings last quarter?
Anika Therapeutics released its earnings results on Aug 08, 2024. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.067 by $0.103.
Is Anika Therapeutics overvalued?
According to Wall Street analysts Anika Therapeutics’s price is currently Undervalued.
Does Anika Therapeutics pay dividends?
Anika Therapeutics does not currently pay dividends.
What is Anika Therapeutics’s EPS estimate?
Anika Therapeutics’s EPS estimate is $0.09.
How many shares outstanding does Anika Therapeutics have?
Anika Therapeutics has 14,796,726 shares outstanding.
What happened to Anika Therapeutics’s price movement after its last earnings report?
Anika Therapeutics reported an EPS of $0.17 in its last earnings report, beating expectations of $0.067. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Anika Therapeutics?
Among the largest hedge funds holding Anika Therapeutics’s share is Diker Management LLC. It holds Anika Therapeutics’s shares valued at 1M.
---
Anika Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.00 (45.27% Upside)
$37.00 (45.27% Upside)
Blogger Sentiment
Bullish
ANIK Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.24%
12-Months-Change
Fundamentals
Return on Equity
-30.63%
Trailing 12-Months
Asset Growth
-20.14%
Trailing 12-Months
Company Description
Anika Therapeutics
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.
---
ANIK Company Deck
---
ANIK Earnings Call
Q2 2024
0:00 / 0:00
---
ANIK Stock 12 Month Forecast
Average Price Target
$37.00
▲(45.27% Upside)
Technical Analysis
Best Analysts Covering ANIK
1 Year
1 Year Success Rate
7/23 ratings generated profit
1 Year Average Return
-5.29%
reiterated a buy rating last month
Copying Michael Petusky's trades and holding each position for 1 Year would result in 30.43% of your transactions generating a profit, with an average return of -5.29% per trade.
---